Bosentan for giant cell arteritis study
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests whether bosentan, a medicine usually used for blood pressure in the lungs, can help control inflammation and symptoms in patients with giant cell arteritis (GCA). The goal is to see if it can reduce the need for steroids and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and have been diagnosed with giant cell arteritis (GCA) by a doctor.
- You have had symptoms of active GCA (like headache, jaw pain, vision changes, or shoulder/hip stiffness) in the past 2 weeks, along with raised inflammation levels (ESR or CRP).
- You haven't taken certain other GCA treatments (like tocilizumab, methotrexate, or cyclophosphamide) for at least 12 weeks before starting the study (unless your doctor says otherwise).
- You do not have serious liver problems (like cirrhosis, hepatitis B or C, or high liver enzymes).
- If you are a woman who could become pregnant, you use a non-hormonal birth control method and have a negative pregnancy test.
- You do not take certain medications like glibenclamide, fluconazole, or rifampicin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.